

AMENDMENTS TO THE CLAIMS

1. (Currently amended): Factor RecA [[with]] comprising an amino acid sequence that is at least identical to 96% [[of]] identical to the amino acid sequence listed in SEQ ID NO: 2 of SEQ ID NO: 2.

2. (Currently amended): The factor according to of claim 1 [[with]] comprising an amino acid sequence that is at least 96.5% identical to the amino acid sequence listed in SEQ ID NO: 2 of SEQ ID NO: 2.

Claims 3–4 (Canceled)

5. (Currently amended): Nucleic acid encoding for A nucleic acid encoding a factor RecA, [[whose]] wherein the nucleotide sequence is at least 85% identical with the nucleotide sequence listed in SEQ ID NO: 1 to the nucleotide sequence of SEQ ID NO: 1.

6. (Currently amended): The nucleic acid according to of claim 5, [[whose]] wherein the nucleotide sequence is at least 87.5% identical to the nucleotide sequence listed in SEQ ID NO: 1 to the nucleotide sequence of SEQ ID NO: 1.

7. (Currently amended): The nucleic acid according to of claim 5, encoding for a factor RecA, wherein the amino acid sequence is at least identical to 96% [[of]] identical to the amino acid sequence listed in SEQ ID NO: 2 of SEQ ID NO: 2.

8. (Previously presented): A method of functionally inactivating the gene *recA* in a gram-positive bacterium that is not *Bacillus megaterium*, said method comprising the step of inactivating said *recA* gene with a nucleic acid sequence that encodes a factor RecA.

9. (Previously presented): The method of claim 8, wherein a nucleic acid that encodes for a non-active protein is introduced with a point mutation.

10. (Currently amended): The method of claim 8, wherein a nucleic acid with a deletion mutation or insertion mutation is employed, preferably comprising each of the boundary

sequences that comprise at least 70 to 150 nucleic acid positions of the region encoding [[for]] the protein.

11. (Currently amended): The method of claim 8, wherein nucleic acids with a total of two nucleic acid segments are employed that each comprise at least 70 to 150 nucleic acid positions and thereby at least partially, preferably completely flank the region encoding [[for]] the protein.

12. (Canceled)

13. (Previously presented): The method of claim 8, wherein the gram-positive bacterium is naturally capable of sporulation and a gene from the phase IV of the sporulation is simultaneously functionally inactivated with *recA*.

14. (Previously presented): The method of claim 13, wherein the inactivated gene from the phase IV sporulation in the nomenclature of *B. subtilis* concerns one of the genes *spoIVVA*, *spoIVB*, *spoIVCA*, *spoIVCB*, *spoIVFA*, *spoIVFB* or *yqfD* or homologue thereof.

15. (Canceled)

16. (Previously presented): The method of claim 14, wherein the functional inactivation of the genes *spoIVVA*, *spoIVB*, *spoIVCA*, *spoIVCB*, *spoIVFA*, *spoIVFB*, *yqfD* or *spoIV* or of each of their homologous genes occurs with the help of the sequences SEQ ID NO. 3, 5, 7, 9, 11, 13, 15 or 17 or parts thereof.

17. (Previously presented): A gram-positive bacterium that is not *Bacillus megaterium* in which the gene *recA* is functionally inactivated.

18. (Currently amended): The gram-positive bacterium according to claim 17, wherein the functional inactivation is effected through point mutagenesis, partial deletion or insertion or total deletion of the encoding region for the complete protein.

19. (Previously presented): The gram-positive bacterium of claim 17, wherein the functional inactivation is effected through a nucleic acid which comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 1.

20. (Currently amended): The gram-positive bacterium of claim 17, wherein said bacterium is naturally capable of sporulation and by which a gene from [[the]] phase IV of the sporulation is simultaneously functionally inactivated with *recA*.

21. (Currently amended): The gram-positive bacterium according to of claim 20, wherein the inactivated gene from the phase IV of the sporulation in the nomenclature of *B. subtilis* concerns one of the genes *spoIVIA*, *spoIVB*, *spoIVCA*, *spoIVCB*, *spoIVFA*, *spoIVFB* or *yqfD* or homologue thereof.

22. (Cancelled)

23. (Previously presented): The gram-positive bacterium of claim 21, wherein the functional inactivation of the genes *spoIVIA*, *spoIVB*, *spoIVCA*, *spoIVCB*, *spoIVFA*, *spoIVFB*, *yqfD* or *spoIV* or of each of their homologous genes is effected with the help of the sequences SEQ ID NO. 3, 5, 7, 9, 11, 13, 15 or 17 or parts thereof.

24. (Currently amended): The gram-positive bacterium of claim 17, wherein said bacterium is from the genera genus Clostridium or Bacillus.

25. (Currently amended): A process for fermenting a gram-positive bacterium comprising the step of fermenting [[a]] the gram-positive bacterium of claim 17.

26. (Currently amended): The process according to of claim 25, wherein said gram-positive bacterium produces a low molecular weight compound or a protein.

27. (Currently amended): The process according to of claim 26, wherein the low molecular weight compound is a natural product, a nutritional supplement or a pharmaceutically relevant compound.

28. (Currently amended): The process according to of claim 26, wherein the protein is an enzyme.

29. (Currently amended): Use-of A method for improving a molecular biological reaction comprising adding the factor RecA of claim 1 in a molecular biological reaction approach.

30. (Currently amended): ~~Use according to The method of claim 29, wherein the molecular biological reaction comprises [[for]] stabilizing single stranded DNA in a DNA polymerization, recombination processes *in vitro*, or converting double stranded DNA into single stranded DNA or vice versa.~~

31. (Previously presented): A vector comprising the nucleic acid of claim 5.

32. (Currently amended): The vector ~~according to of~~ claim 31, wherein said vector is an expression vector.

33. (Currently amended): A process for the manufacture of [[a]] ~~the~~ factor RecA of claim 1.

34. (Currently amended): ~~The process according to of~~ claim 33, ~~under addition of comprising adding~~ the nucleic acid of claim 1 to a host cell.

Claims 35–47 (Canceled)

48. (Previously presented) The method of claim 8, wherein said nucleic acid sequence comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 1.

49. (New): A method for inactivating a factor *recA* gene *in vitro* comprising interaction of the nucleic acid of claim 5 with an associated nucleic acid.

50. (New): A method for amplifying a DNA region *in vivo* comprising orienting against one another two nucleic acids selected from the group consisting of nucleic acids having the sequences of SEQ ID NOs: 25 to 30.

51. (New): The method of claim 50, wherein the DNA region is a *recA* gene.

52. (New): The method of claim 50, wherein the DNA region is a *spoIV* gene.

53. (New): The method of claim 52, further comprising a gram-positive bacterium that is naturally capable of sporulation that is not *Bacillus megaterium*, and wherein a gene from phase IV of sporulation is simultaneously functionally inactivated with *recA*.

54. (New): A method for producing the gram-positive bacterium of claim 20 comprising the method of claim 52.